Top 3 toxoplasma gondii treatment in 2022

Below are the best information and knowledge on the subject toxoplasma gondii treatment compiled and compiled by our own team alltopus:

1. How to Stop the Lurking Toxoplasmosis Parasite? Target Its ‘Stomach’

Author: www.cdc.gov

Date Submitted: 02/25/2020 08:05 PM

Average star voting: 5 ⭐ ( 43607 reviews)

Summary: The stubborn cyst form of a common parasite can’t cause disease without a key digestion factor, new mouse research shows. This suggests an avenue for future treatments.

Match with the search results: Most healthy people recover from toxoplasmosis without treatment. Persons who are ill can be treated with …. read more

How to Stop the Lurking Toxoplasmosis Parasite? Target Its ‘Stomach’

2. Azithromycin is able to control Toxoplasma gondii infection in human villous explants – Journal of Translational Medicine

Author: www.mayoclinic.org

Date Submitted: 01/19/2020 11:44 AM

Average star voting: 4 ⭐ ( 87285 reviews)

Summary: Although Toxoplasma gondii infection is normally asymptomatic, severe cases of toxoplasmosis may occur in immunosuppressed patients or congenitally infected newborns. When a fetal infection is established, the recommended treatment is a combination of pyrimethamine, sulfadiazine and folinic acid (PSA). The aim of the present study was to evaluate the efficacy of azithromycin to control T. gondii infection in human villous explants. Cultures of third trimester human villous explants were infected with T. gondii and simultaneously treated with either PSA or azithromycin. Proliferation of T. gondii, as well as production of cytokines and hormones by chorionic villous explants, was analyzed. Treatment with either azithromycin or PSA was able to control T. gondii infection in villous explants. After azithromycin or PSA treatment, TNF-α, IL-17A or TGF-β1 levels secreted by infected villous explants did not present significant differences. However, PSA-treated villous explants had decreased levels of IL-10 and increased IL-12 levels, while treatment with azithromycin increased production of IL-6. Additionally, T. gondii-infected villous explants increased secretion of estradiol, progesterone and HCG + β, while treatments with azithromycin or PSA reduced secretion of these hormones concurrently with decrease of parasite load. In conclusion, these results suggest that azithromycin may be defined as an effective alternative drug to control T. gondii infection at the fetal-maternal interface.

Match with the search results: If you have HIV / AIDS , the treatment of choice for toxoplasmosis is also pyrimethamine and sulfadiazine, with folinic acid (leucovorin). An ……. read more

Azithromycin is able to control Toxoplasma gondii infection in human villous explants - Journal of Translational Medicine

3. Frontiers | Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs | Cellular and Infection Microbiology

Author: www.cdc.gov

Date Submitted: 10/27/2021 01:56 PM

Average star voting: 3 ⭐ ( 24143 reviews)

Summary: Toxoplasma gondii is the causative agent of toxoplasmosis in animals and humans. This infection is transmitted to humans through oocysts released in the feces of the felines into the environment or by ingestion of undercooked meat. This implies that toxoplasmosis is a zoonotic disease and T. gondii is a foodborne pathogen. In addition, chronic toxoplasmosis in goats and sheep is the cause of recurrent abortions with economic losses in the sector. It is also a health problem in pets such as cats and dogs. Although there are therapies against this infection in its acute stage, they are not able to permanently eliminate the parasite and sometimes they are not well tolerated. To develop better, safer drugs, we need to elucidate key aspects of the biology of T. gondii. In this review, we will discuss the importance of the homologous recombination repair (HRR) pathway in the parasite’s lytic cycle and how components of these processes can be potential molecular targets for new drug development programs. In that sense, the effect of different DNA damage agents or HHR inhibitors on the growth and replication of T. gondii will be described. Multitarget drugs that were either associated with other targets or were part of general screenings are included in the list, providing a thorough revision of the drugs that can be tested in other scenarios.

Match with the search results: Treatment · Pyrimethamine: 2 mg/kg per day orally, divided twice per day for the first 2 days; then from day 3 to 2 months (or 6 months if symptomatic) 1 mg/kg ……. read more

Frontiers | Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs | Cellular and Infection Microbiology

Related Posts

Leave a Reply

Your email address will not be published.